Actuate Closes $11.0M Offering, Nets $9.96M With 46.5M Dilutive Shares and Warrants
ACTU is trading near its 52-week low of $0.35 (9.5% above the low).
Summary
Actuate closed its $11.0 million underwritten offering, netting about $9.96 million from 30,985,900 shares and 15,492,950 warrants priced at $0.71 per two shares and one warrant. For a company that had warned of cash needs and Nasdaq listing risk, the raise extends runway—at the cost of heavy dilution.
Key Events · Financing and Capital Events · ACTU
-
Offering Closes With $9.96M Net
On October 28, 2026, Actuate closed the sale of 30,985,900 shares and 15,492,950 common warrants, netting approximately $9.96 million after underwriting discounts, commissions and estimated expenses.
-
Pricing Terms and Warrant Overhang
Each set of two shares and one warrant was priced at $0.71; the warrants carry a $0.45 exercise price, are immediately exercisable and expire five years after issuance. Full cash exercise would add roughly $7.0 million, though no assurance is given that any warrants will be exercised.
-
Over-Allotment Still Open
The underwriter holds a 45-day option for up to 4,647,885 additional shares and 2,323,942 additional warrants at the same public offering price—further dilution if exercised.
-
Underwriter Compensation
Newbridge Securities received warrants for 3.5% of shares sold (up to 1,247,182 shares) at $0.44375 per share, exercisable beginning 180 days after the underwriting agreement and expiring October 26, 2031; the underwriting discount was $0.0497 per two-share/one-warrant set.
Analysis · ACTU · Life Sciences
The offering Actuate priced on October 27 has closed, bringing in roughly $9.96 million net. That cash matters because the company's last quarterly report showed runway only into September 2026 and an active Nasdaq delisting risk. The cost, however, is steep: 30,985,900 shares plus 15,492,950 warrants (another 4,647,885 shares and 2,323,942 warrants if the over-allotment is exercised) were sold at $0.71 per two shares and one warrant, with warrants struck at $0.45. Against a stock trading near $0.38 today, that is a large share count. Near-term supply is constrained by a 120-day company lock-up and 120-day insider lock-ups (two years for the Bios and Kairos funds), but the dilution itself is not. The underwriter also received warrants for 3.5% of shares sold at $0.44375, exercisable after 180 days.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $0.35 to $7.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.